Klin Onkol 2004; 17(Suppl 1): 11-26.
Summary: Standard data model necessary for evaluation of quality, short-term and long-term results and safety of therapy in oncology is defined. The proposal is based on minimum clinical data set, that includes diagnostic parameters, prognostic factors and time-related identification of risk events (relapse, disease progression, serious complications, etc.). Automatic processing health care data and other common information sources (laboratory data and others). Based on complex evaluation of these data, an indicative outputs for cost-benefit analyses were proposed in graphical tool retlecting key therapeutic aims, both for curable and incurable cases. The proposal is supported by critical evaluation of HT A endpoints, suitable for summarization at the population level and for individua11y-specific assessment of each patient, as well. The standardized assessment procedures are based on benchmarking of actual clinical results according to reference data.
